Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1291 studies found for:    Open Studies | "Leukemia"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   T-cell Large Granular Lymphocyte Leukemia
Interventions: Drug: fludarabine phosphate;   Biological: rituximab;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: pharmacological study
2 Recruiting Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
3 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
4 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Brain Stem Glioma;   Adult Ependymoblastoma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Adult Mixed Glioma;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult Pineal Gland Astrocytoma;   Adult Solid Neoplasm;   AIDS Related Immunoblastic Lymphoma;   AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large Cell Lymphoma;   AIDS-Related Diffuse Mixed Cell Lymphoma;   AIDS-Related Diffuse Small Cleaved Cell Lymphoma;   AIDS-Related Hodgkin Lymphoma;   AIDS-Related Lymphoblastic Lymphoma;   AIDS-Related Lymphoma;   AIDS-Related Primary Central Nervous System Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Cutaneous B-Cell Non-Hodgkin Lymphoma;   Extensive Stage Small Cell Lung Carcinoma;   Extra-Adrenal Paraganglioma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Gastrin-Producing Neuroendocrine Tumor;   Hepatic Complication;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lung Carcinoid Tumor;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Male Breast Carcinoma;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Metastatic Adrenal Gland Pheochromocytoma;   Metastatic Gastrointestinal Neuroendocrine Tumor G1;   Nasal Cavity Inverted Papilloma;   Nodal Marginal Zone Lymphoma;   Olfactory Neuroblastoma;   Pancreatic Glucagonoma;   Pancreatic Insulinoma;   Pancreatic Polypeptide Tumor;   Poorly Differentiated Thyroid Gland Carcinoma;   Recurrent Adrenal Gland Pheochromocytoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Adult T-Cell Leukemia/Lymphoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Gastrointestinal Neuroendocrine Tumor G1;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Hypopharyngeal Squamous Cell Carcinoma;   Recurrent Inverted Schneiderian Papilloma;   Recurrent Laryngeal Squamous Cell Carcinoma;   Recurrent Laryngeal Verrucous Carcinoma;   Recurrent Lip and Oral Cavity Squamous Cell Carcinoma;   Recurrent Lip Basal Cell Carcinoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Melanoma;   Recurrent Merkel Cell Carcinoma;   Recurrent Metastatic Squamous Cell Carcinoma to the Neck With Occult Primary;   Recurrent Mycosis Fungoides and Sezary Syndrome;   Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Recurrent Nasal Type NK/T-Cell Lymphoma;   Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Recurrent Non-Small Cell Lung Carcinoma;   Recurrent Olfactory Neuroblastoma;   Recurrent Oral Cavity Adenoid Cystic Carcinoma;   Recurrent Oral Cavity Mucoepidermoid Carcinoma;   Recurrent Oral Cavity Verrucous Carcinoma;   Recurrent Oropharyngeal Squamous Cell Carcinoma;   Recurrent Oropharyngeal Undifferentiated Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Pancreatic Neuroendocrine Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Salivary Gland Carcinoma;   Recurrent Small Cell Lung Carcinoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Regional Adrenal Gland Pheochromocytoma;   Regional Gastrointestinal Neuroendocrine Tumor G1;   Small Intestinal Lymphoma;   Somatostatin-Producing Neuroendocrine Tumor;   Splenic Marginal Zone Lymphoma;   Squamous Cell Carcinoma Metastatic to the Neck With Occult Primary;   Stage III Adult Soft Tissue Sarcoma;   Stage III Bladder Cancer;   Stage III Hypopharyngeal Squamous Cell Carcinoma;   Stage III Laryngeal Squamous Cell Carcinoma;   Stage III Laryngeal Verrucous Carcinoma;   Stage III Lip and Oral Cavity Squamous Cell Carcinoma;   Stage III Lip Basal Cell Carcinoma;   Stage III Major Salivary Gland Carcinoma;   Stage III Merkel Cell Carcinoma;   Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage III Nasal Type NK/T-Cell Lymphoma;   Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage III Oral Cavity Adenoid Cystic Carcinoma;   Stage III Oral Cavity Mucoepidermoid Carcinoma;   Stage III Oral Cavity Verrucous Carcinoma;   Stage III Oropharyngeal Squamous Cell Carcinoma;   Stage III Oropharyngeal Undifferentiated Carcinoma;   Stage III Pancreatic Cancer;   Stage III Prostate Cancer;   Stage III Renal Cell Cancer;   Stage III Thyroid Gland Follicular Carcinoma;   Stage III Thyroid Gland Papillary Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIA Colon Cancer;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Rectal Cancer;   Stage IIIA Skin Melanoma;   Stage IIIB Breast Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Rectal Cancer;   Stage IIIB Skin Melanoma;   Stage IIIC Breast Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IIIC Skin Melanoma;   Stage IV Adult Soft Tissue Sarcoma;   Stage IV Bladder Cancer;   Stage IV Breast Cancer;   Stage IV Hypopharyngeal Squamous Cell Carcinoma;   Stage IV Merkel Cell Carcinoma;   Stage IV Nasal Type NK/T-Cell Lymphoma;   Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma;   Stage IV Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Pancreatic Cancer;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Stage IV Skin Melanoma;   Stage IVA Basal Cell Lip Carcinoma;   Stage IVA Colon Cancer;   Stage IVA Laryngeal Squamous Cell Carcinoma;   Stage IVA Laryngeal Verrucous Carcinoma;   Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVA Major Salivary Gland Carcinoma;   Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVA Oral Cavity Adenoid Cystic Carcinoma;   Stage IVA Oral Cavity Mucoepidermoid Carcinoma;   Stage IVA Oral Cavity Verrucous Carcinoma;   Stage IVA Oropharyngeal Squamous Cell Carcinoma;   Stage IVA Oropharyngeal Undifferentiated Carcinoma;   Stage IVA Rectal Cancer;   Stage IVA Thyroid Gland Follicular Carcinoma;   Stage IVA Thyroid Gland Papillary Carcinoma;   Stage IVB Basal Cell Lip Carcinoma;   Stage IVB Colon Cancer;   Stage IVB Laryngeal Squamous Cell Carcinoma;   Stage IVB Laryngeal Verrucous Carcinoma;   Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVB Major Salivary Gland Carcinoma;   Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVB Oral Cavity Adenoid Cystic Carcinoma;   Stage IVB Oral Cavity Mucoepidermoid Carcinoma;   Stage IVB Oral Cavity Verrucous Carcinoma;   Stage IVB Oropharyngeal Squamous Cell Carcinoma;   Stage IVB Oropharyngeal Undifferentiated Carcinoma;   Stage IVB Rectal Cancer;   Stage IVB Thyroid Gland Follicular Carcinoma;   Stage IVB Thyroid Gland Papillary Carcinoma;   Stage IVC Basal Cell Lip Carcinoma;   Stage IVC Laryngeal Squamous Cell Carcinoma;   Stage IVC Laryngeal Verrucous Carcinoma;   Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma;   Stage IVC Major Salivary Gland Carcinoma;   Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma;   Stage IVC Oral Cavity Adenoid Cystic Carcinoma;   Stage IVC Oral Cavity Mucoepidermoid Carcinoma;   Stage IVC Oral Cavity Verrucous Carcinoma;   Stage IVC Oropharyngeal Squamous Cell Carcinoma;   Stage IVC Oropharyngeal Undifferentiated Carcinoma;   Stage IVC Thyroid Gland Follicular Carcinoma;   Stage IVC Thyroid Gland Papillary Carcinoma;   T-Cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Thyroid Gland Medullary Carcinoma;   Thyroid Gland Undifferentiated (Anaplastic) Carcinoma;   Tongue Carcinoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: Romidepsin;   Other: Pharmacological Study
5 Recruiting Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia
Intervention: Drug: SG2000
6 Unknown  Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
Conditions: Relapsed Acute Promyelocytic Leukemia;   Refractory Acute Promyelocytic Leukemia
Interventions: Drug: Arsenic trioxide;   Drug: Trisenox
7 Recruiting Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T lymphocytes;   Other: laboratory biomarker analysis
8 Recruiting Natural History Study of Monoclonal B Cell Lymphocytosis and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: B-Cell Chronic Lymphocytic Leukemia;   Monoclonal B-Cell Lymphocytosis;   Lymhoma, Small Lymphocytic;   Chronic Lymphocytic Leukemia
Intervention:
9 Recruiting Ruxolitinib for Adult T-Cell Leukemia
Conditions: T Cell Leukemia, Adult;   Leukemia, Adult T-Cell;   T Cell Leukemia, HTLV I Associated
Intervention: Drug: Ruxolitinib
10 Recruiting Dose Escalation Study of EPZ-5676 in Pediatric Patients With Leukemias Bearing a Rearrangement of the MLL Gene
Conditions: Leukemia;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Acute Leukemias
Intervention: Drug: EPZ-5676
11 Recruiting Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma
Interventions: Biological: Pneumococcal Polyvalent Vaccine;   Drug: Lenalidomide;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
12 Recruiting Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab;   Biological: ofatumumab;   Procedure: biopsy
13 Recruiting Lenalidomide and AT-101 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: lenalidomide;   Drug: R-(-)-gossypol acetic acid
14 Recruiting Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
Conditions: Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia
Interventions: Drug: Ibrutinib;   Biological: Rituximab;   Drug: Bendamustine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment
15 Recruiting Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Anemia;   Fever, Sweat, and Hot Flashes;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma;   Weight Change
Interventions: Drug: Ibrutinib;   Drug: Fludarabine Phosphate;   Drug: Cyclophosphamide;   Biological: Rituximab;   Other: Quality-of-Life Assessment;   Other: Laboratory Biomarker Analysis
16 Not yet recruiting Lenalidomide in Combination With HLA-mismatched Stem-cell Microtransplantation as Post-remission Therapy in Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia (AML);   Acute Myelocytic Leukemia;   Acute Myelogenous Leukemia;   Acute Granulocytic Leukemia;   Acute Non-Lymphocytic Leukemia
Interventions: Drug: Lenalidomide;   Genetic: HLA-mismatched stem-cell Microtransplantation;   Drug: Cytarabine
17 Recruiting Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia
Conditions: Leukemia;   Myelodysplasia;   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia
Interventions: Procedure: Umbilical Cord Blood Transfusion;   Drug: Fludarabine;   Drug: Busulfan;   Drug: Melphalan
18 Recruiting PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: Hedgehog inhibitor PF-04449913
19 Recruiting Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia
Interventions: Dietary Supplement: curcumin;   Dietary Supplement: cholecalciferol;   Other: laboratory biomarker analysis;   Other: pharmacological study
20 Recruiting Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Condition: Leukemia
Interventions: Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years